MX2022016340A - Fusiones heterodimericas de relaxina y usos de las mismas. - Google Patents

Fusiones heterodimericas de relaxina y usos de las mismas.

Info

Publication number
MX2022016340A
MX2022016340A MX2022016340A MX2022016340A MX2022016340A MX 2022016340 A MX2022016340 A MX 2022016340A MX 2022016340 A MX2022016340 A MX 2022016340A MX 2022016340 A MX2022016340 A MX 2022016340A MX 2022016340 A MX2022016340 A MX 2022016340A
Authority
MX
Mexico
Prior art keywords
relaxin
heterodimeric
treatment
fusions
fusion polypeptides
Prior art date
Application number
MX2022016340A
Other languages
English (en)
Inventor
Isabelle Sermadiras
Monika Anna Papworth
Judy Christiane Paterson
Esther Marie Martin
Peng Ke
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2022016340A publication Critical patent/MX2022016340A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a polipéptidos de fusión heterodiméricos de Relaxina, en particular, a polipéptidos de fusión heterodiméricos de Relaxina 2 y a usos de los mismos. Por tanto, la invención proporciona polipéptidos de fusión de Relaxina, moléculas de ácido nucleico, vectores, células hospedadoras, composiciones farmacéuticas y kits que comprenden los mismos y usos de los mismos, incluyendo métodos de tratamiento. Los polipéptidos y las composiciones de la invención pueden ser útiles, en particular, en el tratamiento de enfermedades cardiovasculares, por ejemplo, para el tratamiento de la insuficiencia cardíaca.
MX2022016340A 2020-06-17 2021-06-16 Fusiones heterodimericas de relaxina y usos de las mismas. MX2022016340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063040250P 2020-06-17 2020-06-17
PCT/EP2021/066309 WO2021255127A1 (en) 2020-06-17 2021-06-16 Heterodimeric relaxin fusions and uses thereof

Publications (1)

Publication Number Publication Date
MX2022016340A true MX2022016340A (es) 2023-01-24

Family

ID=76584509

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016340A MX2022016340A (es) 2020-06-17 2021-06-16 Fusiones heterodimericas de relaxina y usos de las mismas.

Country Status (17)

Country Link
US (2) US11795205B2 (es)
EP (1) EP4168434A1 (es)
JP (1) JP2023530335A (es)
KR (1) KR20230024994A (es)
CN (1) CN115916813A (es)
AR (1) AR125007A1 (es)
AU (2) AU2021290997C1 (es)
BR (1) BR112022025019A2 (es)
CA (1) CA3186143A1 (es)
CL (1) CL2022003578A1 (es)
CO (1) CO2023000038A2 (es)
CR (1) CR20230015A (es)
EC (1) ECSP23002960A (es)
IL (1) IL298786A (es)
MX (1) MX2022016340A (es)
TW (1) TW202214673A (es)
WO (1) WO2021255127A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US8389475B2 (en) * 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
CN103429620B (zh) * 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JP2014522641A (ja) * 2011-07-01 2014-09-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リラキシン融合ポリペプチドおよびその使用
AR094147A1 (es) * 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
CA2946503C (en) 2014-05-28 2022-11-22 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
WO2018138170A1 (en) 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof

Also Published As

Publication number Publication date
CA3186143A1 (en) 2021-12-23
AU2021290997B2 (en) 2023-10-12
AU2024200074A1 (en) 2024-01-25
WO2021255127A1 (en) 2021-12-23
EP4168434A1 (en) 2023-04-26
AR125007A1 (es) 2023-05-31
TW202214673A (zh) 2022-04-16
KR20230024994A (ko) 2023-02-21
JP2023530335A (ja) 2023-07-14
BR112022025019A2 (pt) 2022-12-27
US20240025958A1 (en) 2024-01-25
US11795205B2 (en) 2023-10-24
US20220017591A1 (en) 2022-01-20
CO2023000038A2 (es) 2023-01-16
IL298786A (en) 2023-02-01
CN115916813A (zh) 2023-04-04
AU2021290997A1 (en) 2023-02-09
CR20230015A (es) 2023-02-17
AU2021290997C1 (en) 2024-01-04
ECSP23002960A (es) 2023-03-31
CL2022003578A1 (es) 2023-06-09

Similar Documents

Publication Publication Date Title
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
NO20064059L (no) Albumin fusjonsproteiner
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (es) Proteinas de fusion de albumina.
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
DE60336228D1 (de) Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden
WO2007010401A3 (en) Glycosylated il-7, preparation and uses
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
WO2008077945A3 (en) Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
EA201190326A1 (ru) Полипептиды гормона роста и способы их получения и применения
BRPI0609797B8 (pt) nanocorpos melhorados para o tratamento de desordens mediadas por agregação
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
ZA202304098B (en) Il-2 mutants and application thereof
CR20230015A (es) Fusiones heterodiméricas de relaxina y usos de las mismas
WO2016048999A3 (en) Fgf21 truncations and mutants and uses thereof
BR112018076674A2 (pt) proteína de fusão entre o fator de viabilidade do cone derivado de bastonetes de forma curta e um peptídeo hidrofílico
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
EP3239168B1 (en) Derivative of conotoxin peptide kappa-cptx-btl02, preparation method therefor, and uses thereof
BR112022021635A2 (pt) Distrofinas miniaturizadas tendo domínios de fusão de espectrina e usos das mesmas
WO2022219075A3 (en) Peptides, nanovesicles, and uses thereof for drug delivery
EP3252071B1 (en) Conotoxin peptide kappa-cptx-btl03, preparation method therefor, and uses thereof